Clarity Pharmaceuticals (ASX: CU6), an Australia-based, clinical stage radiopharmaceutical company, announced on Thursday that it has started its registrational Phase III 64Cu-SAR-bisPSMA diagnostic trial in prostate cancer, CLARIFY (NCT06056830), with the initiation of the first clinical site at the Urology Cancer Center / XCancer Omaha, NE.
The CLARIFY study's aim is to evaluate the diagnostic performance of 64Cu-SAR-bisPSMA to detect regional nodal metastasis in subjects with high-risk prostate cancer prior to radical prostatectomy. The study is expected to enrol 383 subjects at multiple clinical sites across the United States and Australia.
Assessment is to be conducted over two imaging timepoints, day one (day of administration) and day two (around 24 hours post administration). The study is expected to image the first subject in late 2023. As a registrational trial, the final study results are intended to provide sufficient evidence to support an application to the US FDA for approval of 64Cu-SAR-bisPSMA as a new diagnostic imaging agent in prostate cancer.
Renew Biotechnologies names new chief operating officer
Teva, Sanofi accelerate inflammatory bowel disease drug trial
Ro adds David B Allison to Advisory Board
Charles River Laboratories and Autobahn Labs forge alliance to boost academic drug discovery
Nkarta partnering with Columbia on investigator-led lupus trial for NKX019
Gilead's lenacapavir demonstrates 100% efficacy in HIV prevention trial
Anixa Biosciences' ovarian cancer CAR-T therapy individual patient IND receives FDA approval
Evergreen Nephrology names new director
Emmaus Life Sciences names new chief executive officer
FDA feedback boosts Diamyd Medical's pathway to accelerated approval for Type 1 Diabetes Therapy
TC BioPharm (Holdings) doses sixth patient in TCB-008 clinical trial
Caidya names new chief executive officer
Ionis Pharmaceuticals reports positive results for ION582 in Angelman syndrome study
Nuvalent launches HEROEX-1 trial for HER2-selective inhibitor NVL-330
Astellas and Osaka University collaborate on stem cell therapy for disc degeneration